Capstan Launches, Backed By Big Names And Big Pharma, To Pioneer In Vivo Cell Therapies
Focused on Combining mRNA and CAR technologies
The start-up, founded on science from the University of Pennsylvania, announced a $102m series A financing and the appointment of former Silverback CEO Laura Shawver as CEO.
